ERGO Financials 07/16/2014 16:47:15 Entia Bioscie

ERGO Financials 07/16/2014 16:47:15
Entia Biosciences Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 315 369 403 382
Cost of Revenue 131 107 133 156
Gross Profit 184 262 271 226
Operating Expenses
Research and Development - - - -
Sales, General and Admin. 2,865 1,342 1,637 1,238
Non-Recurring Items 288 - 107 -
Other - - - -
Operating Income (2,970) (1,081) (1,473) (1,011)
Income From Continuing Operations
Add'l Income/Expense Items 10 79 83 3
Earnings Before Interest and Tax (2,960) (1,001) (1,390) (1,008)
Interest Expense 145 263 339 258
Earnings Before Tax (3,105) (1,264) (1,729) (1,266)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (3,105) (1,189) (1,729) (1,266)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (3,105) (1,264) (1,729) (1,266)
Preferred Stock and Other Adjustments (88) (21) - -
Net Income Applicable to Common Shareholders (3,192) (1,286) (1,729) (1,266)